๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Cancer: Where we are now and goals for 2015

โœ Scribed by Gerald L. Woolam

Publisher
John Wiley and Sons
Year
2000
Tongue
English
Weight
79 KB
Volume
75
Category
Article
ISSN
0022-4790

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Lead and cancer in humans: Where are we
Lead and cancer in humans: Where are we now?
โœ Kyle Steenland; Paolo Boffetta ๐Ÿ“‚ Article ๐Ÿ“… 2000 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 124 KB ๐Ÿ‘ 1 views
Understanding diabetic teratogenesis: Wh
Understanding diabetic teratogenesis: Where are we now and where are we going?
โœ Sheller Zabihi; Mary R. Loeken ๐Ÿ“‚ Article ๐Ÿ“… 2010 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 154 KB ๐Ÿ‘ 2 views

## Abstract Maternal pregestational diabetes (type 1 or type 2) poses an increased risk for a broad spectrum of birth defects. To our knowledge, this problem first came to the attention of the Teratology Society at the 14th Annual Meeting in Vancouver, B.C. in 1974, with a presentation by Lewis Hol

Teaching Style: Where Are We Now?
Teaching Style: Where Are We Now?
โœ Joe E. Heimlich; Emmalou Norland ๐Ÿ“‚ Article ๐Ÿ“… 2002 ๐Ÿ› John Wiley and Sons โš– 49 KB ๐Ÿ‘ 2 views
Dopamine D1 receptor ligands: Where are
Dopamine D1 receptor ligands: Where are we now and where are we going
โœ Jing Zhang; Bing Xiong; Xuechu Zhen; Ao Zhang ๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 285 KB

The dopamine (DA) D(1) receptor is the most highly expressed DA receptor subtype among the DA receptor family. Although the first DA D(1) receptor selective ligand SCH-23390 (1) was introduced more than two decades ago, clinically useful D(1) receptor selective ligands are rare. A renewed interest w